{"id":"https://openalex.org/W7204850558","doi":"https://doi.org/10.3389/frhem.2026.1959952","title":"Editorial: New molecular targets for personalized treatment for low-grade non-hodgkin lymphoma","display_name":"Editorial: New molecular targets for personalized treatment for low-grade non-hodgkin lymphoma","alternate_titles":[],"publication_year":2026,"publication_date":"2026-08-31","ids":{"openalex":"https://openalex.org/W7204850558","doi":"https://doi.org/10.3389/frhem.2026.1959952"},"language":"en","primary_location":{"id":"doi:10.3389/frhem.2026.1959952","doi":"https://doi.org/10.3389/frhem.2026.1959952","is_oa":true,"landing_page_url":"https://doi.org/10.3389/frhem.2026.1959952","pdf_url":"https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2026.1959952/pdf","source":{"id":"https://openalex.org/S4387283458","display_name":"Frontiers in Hematology","issn_l":"2813-3935","issn":["2813-3935"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Hematology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W7204850558"],"child_works_count":0,"type":"editorial","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2026.1959952/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042091314","display_name":"Andrea Visentin","orcid":"https://orcid.org/0000-0003-0271-7200","observed_orcids":["https://orcid.org/0000-0003-0271-7200"]},"institutions":[{"id":"https://openalex.org/I138689650","display_name":"University of Padua","ror":"https://ror.org/00240q980","country_code":"IT","type":"education","lineage":["https://openalex.org/I138689650"]},{"id":"https://openalex.org/I4210146744","display_name":"Azienda Ospedale - Universit\u00e0 Padova","ror":"https://ror.org/04bhk6583","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210146744"]}],"countries":["IT"],"is_corresponding":true,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/writing-original-draft","display_name":"Writing \u2013 original draft"},{"id":"https://openalex.org/contributor-roles/writing-review-editing","display_name":"Writing \u2013 review & editing"}],"raw_author_name":"Andrea Visentin","raw_affiliation_strings":["Hematology Unit, Department of Medicine, University of Padova, Azienda Ospedale - Universit\u00e0 Padova, Padova, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Unit, Department of Medicine, University of Padova, Azienda Ospedale - Universit\u00e0 Padova, Padova, Italy","institution_ids":["https://openalex.org/I138689650","https://openalex.org/I4210146744"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5042091314"],"corresponding_institution_ids":["https://openalex.org/I138689650","https://openalex.org/I4210146744"],"apc_list":{"value":1950,"currency":"CHF","value_usd":2353},"apc_paid":{"value":1950,"currency":"CHF","value_usd":2353},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"5","issue":null,"first_page":"1959952","last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.009700000286102295,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/low-grade-non-hodgkin-lymphoma","display_name":"low-grade non-Hodgkin's lymphoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/personalized-treatment","display_name":"personalized treatment","score":0.5400000214576721},{"id":"https://openalex.org/keywords/molecular-targets","display_name":"molecular targets","score":0.7770000100135803},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6320000290870667},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.6200000047683716},{"id":"https://openalex.org/keywords/ezh2","display_name":"EZH2","score":0.7620000243186951},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9980000257492065},{"id":"https://openalex.org/keywords/burkitt-lymphoma","display_name":"Burkitt lymphoma","score":0.9120000004768372},{"id":"https://openalex.org/keywords/waldenstrom-macroglobulinemia","display_name":"Waldenstr\u00f6m macroglobulinemia","score":0.968999981880188},{"id":"https://openalex.org/keywords/myd88-mutation","display_name":"MYD88 mutation","score":0.8270000219345093},{"id":"https://openalex.org/keywords/cxcr4-mutation","display_name":"CXCR4 mutation","score":0.9319999814033508},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.75},{"id":"https://openalex.org/keywords/b-cell-lymphoma","display_name":"B-cell lymphoma","score":0.4699999988079071},{"id":"https://openalex.org/keywords/epigenetic-regulation","display_name":"epigenetic regulation","score":0.4959999918937683}],"concepts":[{"id":"https://openalex.org/C41091548","wikidata":"https://www.wikidata.org/wiki/Q26939","display_name":"Epigenetics","level":3,"score":0.5934000015258789},{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.5789999961853027},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5206000208854675},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5198000073432922},{"id":"https://openalex.org/C32220436","wikidata":"https://www.wikidata.org/wiki/Q2072214","display_name":"Personalized medicine","level":2,"score":0.5005999803543091},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4681999981403351},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4350999891757965},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42649999260902405},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.421999990940094},{"id":"https://openalex.org/C50171091","wikidata":"https://www.wikidata.org/wiki/Q17917770","display_name":"EZH2","level":4,"score":0.4196000099182129},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3779999911785126},{"id":"https://openalex.org/C163763905","wikidata":"https://www.wikidata.org/wiki/Q17075943","display_name":"Precision medicine","level":2,"score":0.3776000142097473},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3666999936103821},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.36489999294281006},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.35580000281333923},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.33320000767707825},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.33149999380111694},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.30720001459121704},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.29670000076293945},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.2806999981403351},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2786000072956085},{"id":"https://openalex.org/C3019816032","wikidata":"https://www.wikidata.org/wiki/Q2575340","display_name":"Cancer treatment","level":3,"score":0.260699987411499},{"id":"https://openalex.org/C128544194","wikidata":"https://www.wikidata.org/wiki/Q474859","display_name":"Translational research","level":2,"score":0.2517000138759613}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.3389/frhem.2026.1959952","doi":"https://doi.org/10.3389/frhem.2026.1959952","is_oa":true,"landing_page_url":"https://doi.org/10.3389/frhem.2026.1959952","pdf_url":"https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2026.1959952/pdf","source":{"id":"https://openalex.org/S4387283458","display_name":"Frontiers in Hematology","issn_l":"2813-3935","issn":["2813-3935"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Hematology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:25135095c8704da9b266f95274ac202f","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/25135095c8704da9b266f95274ac202f","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Hematology, Vol 5 (2026)","raw_type":"article"},{"id":"pmh:oai:www.research.unipd.it:11577/3609599","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/11577/3609599","pdf_url":null,"source":{"id":"https://openalex.org/S4306402547","display_name":"Padua Research Archive (University of Padova)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I138689650","host_organization_name":"University of Padua","host_organization_lineage":["https://openalex.org/I138689650"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.3389/frhem.2026.1959952","doi":"https://doi.org/10.3389/frhem.2026.1959952","is_oa":true,"landing_page_url":"https://doi.org/10.3389/frhem.2026.1959952","pdf_url":"https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2026.1959952/pdf","source":{"id":"https://openalex.org/S4387283458","display_name":"Frontiers in Hematology","issn_l":"2813-3935","issn":["2813-3935"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Hematology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7204850558.pdf","grobid_xml":"https://content.openalex.org/works/W7204850558.grobid-xml"},"referenced_works_count":18,"referenced_works":["https://openalex.org/W3089334610","https://openalex.org/W4224242612","https://openalex.org/W4368362053","https://openalex.org/W4377942447","https://openalex.org/W4396702123","https://openalex.org/W4396899967","https://openalex.org/W4404497069","https://openalex.org/W4407770240","https://openalex.org/W4411522416","https://openalex.org/W4411556631","https://openalex.org/W4414347945","https://openalex.org/W4417091922","https://openalex.org/W4417449624","https://openalex.org/W7140138316","https://openalex.org/W7153177894","https://openalex.org/W7166860070","https://openalex.org/W7171720999","https://openalex.org/W7172431060"],"related_works":["https://openalex.org/W4312296170","https://openalex.org/W2284764035","https://openalex.org/W4396915257","https://openalex.org/W2027442743","https://openalex.org/W2907984340","https://openalex.org/W149965756","https://openalex.org/W99461102","https://openalex.org/W88819536","https://openalex.org/W1981177853","https://openalex.org/W2356145314"],"abstract_inverted_index":{"The":[0,208,343,484,511,537,711,764,857,1090],"therapeutic":[1,83,103,146,178,299,312,377,498,559,591,613,895,962,1100,1238],"landscape":[2],"of":[3,52,155,170,176,185,214,288,301,387,396,467,494,503,514,520,528,544,577,605,611,648,730,770,818,849,862,909,944,1050,1081,1095,1115,1124,1143,1187,1220],"low-grade":[4,151,270,280,631,1167],"non-Hodgkin":[5,1168],"lymphoma":[6,142,171,191,262,266,408,440,606,623,627,666,685,718,732,762,910,1070,1085,1116,1188],"(LG-NHL)":[7],"has":[8,323,995],"evolved":[9],"considerably":[10],"over":[11],"the":[12,31,47,91,137,160,174,200,215,220,238,272,285,295,309,371,384,425,433,461,465,504,553,562,587,609,633,645,659,727,742,768,826,831,839,860,897,906,942,957,1122,1141,1175,1184,1218,1233],"past":[13],"decade,":[14],"driven":[15],"by":[16,46,411],"advances":[17,121,346,973,1083,1249],"in":[18,39,189,347,390,401,430,518,618,676,695,719,735,774,809,974,1015,1084,1156,1171,1250],"molecular":[19,48,96,336,529,915,1011,1052,1126,1145,1191],"biology,":[20],"genomic":[21,50],"profiling,":[22,1053],"and":[23,49,60,85,98,131,144,153,173,187,195,205,219,248,283,340,361,379,448,550,590,608,643,668,687,707,753,778,790,799,806,854,887,952,977,987,1036,1058,1087,1107,1149,1161,1228,1253,1263,1278],"cancer":[24],"immunology":[25],"(1)(2)(3).":[26],"These":[27,235],"developments":[28],"have":[29,662,681],"accelerated":[30],"transition":[32],"from":[33,893],"conventional":[34,938,1214],"chemoimmunotherapy":[35],"to":[36,70,93,444,474,507,534,558,703,761,872,920,925,928,935,984,990,1041,1131,1139,1196,1201,1204,1211,1260,1266],"precision":[37,328,677,696,1136],"medicine,":[38],"which":[40],"treatment":[41,331,375,423,579,702,885,970,986,1004,1246,1262],"decisions":[42],"are":[43,64,276,452,637,980,1256],"increasingly":[44,333],"guided":[45],"characteristics":[51],"individual":[53],"patients":[54,315,889,1165],"(4)(5)(6)(7)(8)(9)(10).":[55],"Targeted":[56],"therapies,":[57],"immune-based":[58],"approaches,":[59,147,592],"biomarker-driven":[61,1059],"risk":[62,756,874,1268],"stratification":[63],"reshaping":[65],"clinical":[66,125,381,394,420,459,492,709,776,869,921,1007,1047,1060,1109,1129,1197],"practice,":[67],"offering":[68],"opportunities":[69],"improve":[71,1132],"efficacy":[72],"while":[73,231,479,1019],"minimizing":[74],"treatment-related":[75],"toxicity":[76],"(11)(12)(13)(14)(15).":[77],"Despite":[78],"these":[79,292,1119],"advances,":[80],"disease":[81,477,851],"heterogeneity,":[82],"resistance,":[84,1101],"relapse":[86],"remain":[87,1000],"significant":[88,998],"challenges,":[89],"underscoring":[90],"need":[92],"identify":[94,888],"new":[95],"targets":[97,1012],"develop":[99],"more":[100,968,1158,1244],"effective":[101,449,1150],"personalized":[102,388,819,1003,1088],"strategies":[104,451],"(16)(17)(18)(19).":[105],"This":[106,416],"Research":[107,1075],"Topic,":[108],"New":[109],"Molecular":[110],"Targets":[111],"for":[112,115,253,314,327,532,571,961,966,1164,1237,1242],"Personalized":[113],"Treatment":[114],"Low-Grade":[116],"Non-Hodgkin":[117],"Lymphoma,":[118],"highlights":[119],"recent":[120],"spanning":[122],"laboratory":[123,1043],"investigations,":[124],"studies,":[126,1018],"translational":[127,1034],"research,":[128],"comprehensive":[129,526,771,1051],"reviews,":[130],"an":[132,264,625,673,692],"instructive":[133],"case":[134,712,724],"report.":[135],"Although":[136,260,455,581,621,653],"articles":[138,899,1177],"focus":[139],"on":[140,335,457,583,655],"distinct":[141],"subtypes":[143,519,667,686],"their":[145],"including":[148,338],"3":[149,154],"about":[150],"lymphomas":[152,282,642],"aggressive":[156,265,626],"lymphomas,":[157],"they":[158,593],"share":[159,594],"common":[161,596,755],"objective:":[162,597],"improving":[163,598,981,1257],"patient":[164,599,1027,1133],"outcomes":[165,421,600,1163],"through":[166,601,941,1217],"a":[167,250,269,325,525,595,602,630,720,723,800,842,1078],"deeper":[168,603],"understanding":[169,566,604,956,1114,1232],"biology":[172,607,671,690,1086],"development":[175,610,943,1219],"individualized":[177,374,612,708,881,1069],"interventions.The":[179],"original":[180],"research":[181,911],"article":[182,297],"\"Dual":[183],"targeting":[184],"EZH2":[186,218],"PD-L1":[188,224],"Burkitt's":[190],"enhances":[192],"immune":[193,221,233,945,1098,1221],"activation":[194,543],"induces":[196],"apoptotic":[197],"pathway\"":[198],"investigates":[199],"interaction":[201],"between":[202,1031],"epigenetic":[203,241,256,548,1096],"regulation":[204],"tumor":[206,246,554],"immunity.":[207],"authors":[209,372,538],"demonstrate":[210,1023],"that":[211,240,565,758,786,846,904,1111,1182],"simultaneous":[212],"inhibition":[213],"histone":[216],"methyltransferase":[217],"checkpoint":[222,946,1222],"molecule":[223],"produces":[225],"synergistic":[226],"antitumor":[227],"activity,":[228],"increasing":[229],"apoptosis":[230],"promoting":[232],"activation.":[234],"findings":[236,485],"support":[237],"concept":[239],"remodeling":[242],"can":[243],"enhance":[244],"immune-mediated":[245],"elimination":[247],"provide":[249],"strong":[251],"rationale":[252],"combining":[254,468,863],"targeted":[255,509,701],"therapy":[257],"with":[258,316,414,424,432,471,830,867,1128,1166],"immunotherapy.":[259],"Burkitt":[261,622],"is":[263,399,569,624,917,1193],"rather":[267,628],"than":[268,629],"subtype,":[271,632],"biological":[273,634,789,930,958,1206,1234],"mechanisms":[274,568,635,959,1094,1235],"explored":[275,636],"broadly":[277,638],"applicable":[278,639],"across":[279,640,665,684,1025],"B-cell":[281,392,641],"illustrate":[284,644,900,1178],"expanding":[286,646],"potential":[287,647],"rational":[289,573,649],"combination":[290,431,497,574,650,1151],"therapies.Complementing":[291],"mechanistic":[293],"findings,":[294],"review":[296,344,563],"\"The":[298],"perspective":[300],"relapsed/refractory":[302],"Waldenstr\u00f6m":[303,321],"Macroglobulinemia:":[304],"what":[305],"comes":[306],"next?\"":[307],"summarizes":[308],"rapidly":[310],"evolving":[311],"options":[313],"relapsed":[317],"or":[318,403],"refractory":[319,404],"disease.":[320],"macroglobulinemia":[322],"become":[324],"model":[326,845],"medicine":[329,698],"because":[330],"selection":[332],"depends":[334],"alterations,":[337,549],"MYD88":[339],"CXCR4":[341],"mutations.":[342],"discusses":[345],"next-generation":[348],"Bruton":[349],"tyrosine":[350],"kinase":[351,515,535],"inhibitors,":[352,947,1223],"BCL2":[353],"inhibition,":[354],"CXCR4-targeted":[355],"agents,":[356,752],"bispecific":[357,427,495,948,1224],"antibodies,":[358,949,1225],"antibodydrug":[359],"conjugates,":[360],"chimeric":[362],"antigen":[363],"receptor":[364],"T-cell":[365,522,585,657],"therapy.":[366,510,1089],"Beyond":[367],"describing":[368],"emerging":[369],"drugs,":[370,951,1227],"emphasize":[373],"selection,":[376,886],"sequencing,":[378],"biomarker-guided":[380],"decisionmaking,":[382,1198],"illustrating":[383],"growing":[385],"complexity":[386],"management":[389],"indolent":[391],"malignancies.The":[393],"application":[395],"innovative":[397,1102],"immunotherapy":[398,933,1209],"illustrated":[400],"\"Relapsed":[402],"central":[405],"nervous":[406,438],"system":[407,439],"successfully":[409],"treated":[410],"glofitamab":[412,429],"combined":[413],"lenalidomide.\"":[415],"report":[417,713,765],"describes":[418,726],"encouraging":[419],"following":[422],"CD20\u00d7CD3":[426],"antibody":[428],"immunomodulatory":[434,472,950,1226],"agent":[435],"lenalidomide.":[436],"Central":[437],"remains":[441,501,964,1240],"particularly":[442],"difficult":[443],"treat":[445],"after":[446],"relapse,":[447],"chemotherapy-free":[450],"urgently":[453],"needed.":[454],"based":[456],"limited":[458],"experience,":[460],"favorable":[462],"response":[463],"demonstrates":[464,859],"promise":[466],"immune-engaging":[469],"therapies":[470,575,924,1152,1200],"agents":[473],"achieve":[475],"durable":[476,969,1159,1245],"control":[478],"potentially":[480],"reducing":[481],"treatment-associated":[482],"toxicity.":[483],"contribute":[486,557,760],"valuable":[487],"preliminary":[488],"evidence":[489],"supporting":[490],"future":[491,788,907,1185],"evaluation":[493],"antibody-based":[496],"strategies.Treatment":[499],"resistance":[500,517,533,567,670,689,963,1239],"one":[502],"greatest":[505],"barriers":[506],"successful":[508],"mini-review":[512],"\"Mechanisms":[513],"inhibitor":[516],"cutaneous":[521,584,656],"lymphomas\"":[523],"provides":[524,1077],"overview":[527,1080],"pathways":[530],"responsible":[531,960,1236],"inhibitors.":[536],"describe":[539],"how":[540,780],"genetic":[541],"mutations,":[542],"compensatory":[545],"signaling":[546],"pathways,":[547],"changes":[551],"within":[552],"microenvironment":[555],"collectively":[556],"failure.":[560],"Importantly,":[561],"emphasizes":[564,767],"essential":[570,816,965,1040,1241],"developing":[572,733],"capable":[576],"restoring":[578],"sensitivity.":[580],"focused":[582,654],"lymphoma,":[586,658],"ha":[588,616,1269,1273,1276],"eliminato:":[589,615,652,1274,1277],"interventions.ha":[614],"spostato":[617,1170,1270],"basso":[619,1172],"[1]:":[620],"therapies.ha":[651],"concepts":[660,679],"discussed":[661,680],"broad":[663,682],"relevance":[664,683],"highlight":[669,688],"as":[672,691],"important":[674,693],"frontier":[675,694],"oncology":[678,1275],"hematology.Personalized":[697],"extends":[699],"beyond":[700,937,1213],"encompass":[704],"careful":[705],"diagnosis":[706],"evaluation.":[710],"\"Synchronous":[714],"mucosa-associated":[715],"lymphoid":[716,1280],"tissue":[717],"married":[721],"couple:":[722],"report\"":[725],"rare":[728,781,1108],"occurrence":[729],"MALT":[731],"simultaneously":[734],"spouses.":[736],"While":[737],"causality":[738],"cannot":[739],"be":[740,926,1039,1154,1202],"established,":[741],"observation":[743],"raises":[744],"intriguing":[745],"questions":[746],"regarding":[747],"shared":[748],"environmental":[749],"exposures,":[750],"infectious":[751],"other":[754],"factors":[757,871],"may":[759,783,879,891],"pathogenesis.":[763,1117],"also":[766],"importance":[769,1123],"diagnostic":[772],"assessment":[773],"unusual":[775],"presentations":[777],"illustrates":[779],"cases":[782],"generate":[784],"hypotheses":[785],"stimulate":[787],"epidemiological":[791],"research.The":[792],"final":[793],"contribution,":[794],"\"Baseline":[795],"Systemic":[796],"Immune-Inflammation":[797],"Index":[798,837],"Novel":[801],"FLIPI-SII":[802],"Model":[803],"Predict":[804],"POD24":[805],"Long-Term":[807],"Survival":[808],"Grade":[810],"1-3a":[811],"Follicular":[812,833],"Lymphoma,\"":[813],"addresses":[814],"another":[815],"component":[817],"medicine:":[820],"accurate":[821],"prognostic":[822,844,870,975,1104,1251],"assessment.":[823],"By":[824],"integrating":[825,1125],"systemic":[827],"immune-inflammation":[828],"index":[829],"established":[832,868],"Lymphoma":[834],"International":[835],"Prognostic":[836],"(FLIPI),":[838],"investigators":[840],"propose":[841],"novel":[843,1144],"improves":[847],"prediction":[848,877],"early":[850],"progression":[852],"(POD24)":[853],"long-term":[855],"survival.":[856],"study":[858],"value":[861],"host":[864],"inflammatory":[865],"biomarkers":[866,976,1021,1252],"refine":[873],"stratification.":[875],"Improved":[876],"models":[878,979,1255],"facilitate":[880],"surveillance":[882],"strategies,":[883],"optimize":[884],"who":[890],"benefit":[892],"earlier":[894],"intervention.Collectively,":[896],"six":[898,1176],"several":[901,1179],"overarching":[902,1180],"themes":[903,1181],"define":[905,1183],"direction":[908,1186],"(Figure":[912],"1).":[913],"First,":[914,1190],"characterization":[916,1192],"becoming":[918,1194],"fundamental":[919,1093,1195],"decision-making,":[922],"enabling":[923,1199],"matched":[927,1203],"specific":[929,1205],"alterations.":[931,1207],"Second,":[932,1208],"continues":[934,1138,1210],"expand":[936,1212],"monoclonal":[939,1215],"antibodies":[940,1216],"cellular":[953,1229],"therapies.":[954,1230],"Third,":[955,1231],"designing":[967,1243],"strategies.":[971,1247],"Finally,":[972,1248],"predictive":[978,1020,1254],"clinicians'":[982,1258],"ability":[983,1259],"individualize":[985,1261],"follow-up":[988,1264],"according":[989,1265],"patient-specific":[991,1267],"risk.Although":[992],"substantial":[993],"progress":[994,1066],"been":[996],"achieved,":[997],"challenges":[999],"before":[1001],"fully":[1002],"becomes":[1005],"routine":[1006],"practice.":[1008],"Many":[1009],"promising":[1010],"require":[1013],"validation":[1014],"prospective":[1016],"multicenter":[1017],"must":[1022],"reproducibility":[1024],"diverse":[1026],"populations.":[1028],"Continued":[1029],"collaboration":[1030],"basic":[1032],"scientists,":[1033],"investigators,":[1035],"clinicians":[1037],"will":[1038,1063,1153],"translate":[1042],"discoveries":[1044],"into":[1045],"meaningful":[1046],"benefit.":[1048],"Integration":[1049],"multi-omic":[1054],"technologies,":[1055],"artificial":[1056],"intelligence,":[1057],"trial":[1061],"designs":[1062],"further":[1064],"accelerate":[1065],"toward":[1067],"truly":[1068],"care.":[1071,1134],"In":[1072],"summary,":[1073],"this":[1074],"Topic":[1076],"timely":[1079],"contemporary":[1082],"contributions":[1091],"span":[1092],"regulation,":[1097],"modulation,":[1099],"immunotherapies,":[1103],"biomarker":[1105],"development,":[1106],"observations":[1110],"broaden":[1112],"our":[1113],"Together,":[1118],"studies":[1120],"reinforce":[1121],"insights":[1127],"innovation":[1130],"As":[1135],"hematology":[1137],"evolve,":[1140],"identification":[1142],"targets,":[1146],"validated":[1147],"biomarkers,":[1148],"instrumental":[1155],"achieving":[1157],"responses":[1160],"better":[1162],"lymphoma.ha":[1169],"[2]:":[1173],"Collectively,":[1174],"research.":[1189],"(inserimento)":[1271],"[2]":[1272],"related":[1279],"malignancies":[1281]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7204850558","counts_by_year":[],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2026-09-01T00:00:00"}
